血液檢測市場機會、成長要素、產業趨勢分析及2026年至2035年預測

2025 年全球血液檢測市場價值 895 億美元，預計到 2035 年將以 7.4% 的複合年成長率成長，達到 1,798 億美元。

慢性病和感染疾病的上升、診斷技術的持續創新以及就地檢驗設施的快速成長是推動市場擴張的主要因素。全球醫療費用支出的成長進一步增強了市場勢頭，使醫院和實驗室能夠投資於自動化系統、先進的分析儀器和高品質的耗材，從而提高診斷準確性和工作流程效率。政府主導的醫療改革、優惠的報銷方案以及擴大的保險覆蓋範圍也促進了常規診斷篩檢和疾病早期發現。在發展中地區，基礎設施建設和協作醫療模式的推進正在加速現代診斷服務的普及。血液檢測在臨床決策中發揮著至關重要的作用；透過測量細胞和生化參數，對血液樣本進行檢查室分析，有助於疾病診斷、健康評估、治療後續觀察和器官功能評估。

預計到2025年，血液常規檢查市場規模將達到132億美元，佔全球市場佔有率的14.7%。血液常規檢查檢測因其能夠提供全面的健康訊息，仍然是應用最廣泛的診斷程序之一。透過評估各種血液成分，該檢測有助於發現血液學異常和全身性疾病。其在預防醫學、治療前評估和持續健康監測中的常規應用，確保了醫院、獨立實驗室和分散式檢查機構的持續需求。全血球計數檢測的臨床意義和廣泛效用使其成為全球血液檢測產業的基礎要素。

預計到2025年，試劑和試劑盒市場規模將達到527億美元，佔整個市場的58.8%。試劑和試劑盒是診斷檢測的基礎，包含用於準確檢體分析所需的特殊化學成分和即用型組件。這些產品廣泛應用於多個診斷領域，確保生物標記和疾病指標的可靠識別。它們在各種檢測程序中的重複使用為製造商提供了穩定的收入來源。對能夠提供精確且可重複結果的標準化、高品質試劑的需求持續推動著該細分市場的成長，並鞏固了其在檢查室操作中的關鍵作用。

預計到2025年，美國血液檢測市場規模將達253億美元。這主要得益於慢性病的高發生率，而慢性病需要定期進行診斷監測。持續的疾病監測、早期療育策略和長期治療管理都高度依賴檢查室血液分析。為了滿足日益成長的診斷需求，醫療機構正擴大採用自動化、高通量檢測平台，旨在提高效率、準確性和結果報告速度。對先進檢測技術的投資依然強勁，進一步鞏固了美國在全球血液檢測市場的地位。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 慢性病和感染疾病的增加加重了負擔
    • 血液檢測設備的技術進步
    • 即時檢測中心數量激增
    • 醫療費用支出增加和有利政策
  • 產業潛在風險與挑戰
    • 血液檢測設備高成本
    • 與血液檢測過程相關的錯誤
  • 市場機遇
    • 家庭和遠端測試解決方案
• 成長潛力分析
• 監理情勢
• 技術進步
  • 當前技術趨勢
  • 新興技術
• 2024年價格分析
• 未來市場趨勢
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 公司矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 合作夥伴關係和合資企業
  • 新產品發布
  • 擴張計劃

第5章 市場估計與預測：依測試類型分類，2022-2035年

• 血液常規檢查
• 血糖測試
• 心臟檢查
• 傳染病篩檢
• 腎功能檢查 - 腎功能指標
• 膽固醇檢測 - 血脂分析
• 癌症篩檢
• 尿液檢查
• 抗體檢測 - 類風濕因子
• 其他類型的測試

第6章 市場估算與預測：依產品分類，2022-2035年

• 試劑和試劑盒
• 裝置
• 軟體

第7章 市場估計與預測：依方法分類，2022-2035年

• 自動化
• 手動的

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 醫院
• 病理檢查室
• 血庫
• 診斷中心
• 其他最終用戶

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第10章：公司簡介

• Danaher
• F Hoffmann-La Roche Ltd.
• Abbott Laboratories
• BioMerieux SA
• Grifols
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Siemens Healthineers
• Sinocare Inc.
• Trinity Biotech
• Thermo Fisher Scientific Inc.
• B. Braun Melsungen AG

The Global Blood Testing Market was valued at USD 89.5 billion in 2025 and is estimated to grow at a CAGR of 7.4% to reach USD 179.8 billion by 2035.

Market expansion is fueled by the rising incidence of chronic and infectious diseases, continuous innovation in diagnostic technologies, and the rapid growth of point-of-care testing facilities. Increasing healthcare expenditure worldwide is further strengthening market momentum, enabling hospitals and laboratories to invest in automated systems, advanced analyzers, and high-quality consumables that enhance diagnostic precision and workflow efficiency. Government-backed healthcare reforms, favorable reimbursement structures, and expanded insurance coverage are also encouraging routine diagnostic screening and early disease detection. In developing regions, infrastructure upgrades and collaborative healthcare models are accelerating access to modern diagnostic services. Blood testing plays a critical role in clinical decision-making, as laboratory analysis of blood samples supports disease diagnosis, health assessment, therapeutic monitoring, and evaluation of organ function through the measurement of cellular and biochemical parameters.

The complete blood count segment generated USD 13.2 billion in 2025 and accounted for 14.7% share. Complete blood count testing remains one of the most widely performed diagnostic procedures due to its ability to provide comprehensive information about overall health status. By evaluating various blood components, this test supports the detection of hematological abnormalities and systemic conditions. Its routine application in preventive care, pre-procedural assessments, and ongoing health monitoring ensures sustained demand across hospitals, independent laboratories, and decentralized testing environments. The consistent clinical relevance and broad utility of complete blood count testing have positioned it as a foundational component of the global blood testing industry.

The reagents and kits segment reached USD 52.7 billion in 2025, representing a substantial 58.8% share. Reagents and kits form the backbone of diagnostic testing, as they contain specialized chemical formulations and ready-to-use components required for accurate sample analysis. These products are utilized across multiple diagnostic disciplines, ensuring reliable identification of biomarkers and disease indicators. Their recurring consumption in every testing procedure drives consistent revenue generation for manufacturers. The need for standardized, high-quality reagents that deliver precise and reproducible results continues to propel segment growth, reinforcing their indispensable role in laboratory operations.

U.S. Blood Testing Market reached USD 25.3 billion in 2025, supported by a high prevalence of chronic health conditions requiring regular diagnostic monitoring. Continuous disease surveillance, early intervention strategies, and long-term treatment management depend heavily on laboratory-based blood analysis. To address rising diagnostic volumes, healthcare providers are adopting automated and high-throughput testing platforms designed to improve efficiency, accuracy, and turnaround times. Investment in advanced laboratory technologies remains strong, further strengthening the country's position within the global blood testing landscape.

Key participants operating in the Global Blood Testing Market include Abbott Laboratories, Danaher, Siemens Healthineers, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Grifols, Trinity Biotech, Sinocare Inc, BioMerieux SA, and B. Braun Melsungen AG. Companies in the blood testing market are reinforcing their competitive edge through strategic product innovation and portfolio expansion. Continuous investment in research and development enables the introduction of advanced diagnostic platforms, automated analyzers, and high-sensitivity reagents that improve accuracy and efficiency. Many organizations are forming strategic collaborations and distribution partnerships to expand geographic reach and strengthen supply chain capabilities. Firms are also focusing on regulatory approvals and quality certifications to enhance credibility and market acceptance. Expansion into emerging economies through localized manufacturing and service networks is another key growth strategy.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Test type trends
  • 2.2.3 Product trends
  • 2.2.4 Method trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing burden of chronic and infectious diseases
    • 3.2.1.2 Technological advancements in blood testing devices
    • 3.2.1.3 Burgeoning number of point-of-care (POC) testing centers
    • 3.2.1.4 Increasing healthcare expenditure and favorable policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of blood testing devices
    • 3.2.2.2 Errors associated with blood testing process
  • 3.2.3 Market opportunities
    • 3.2.3.1 Home-based and remote testing solutions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis, 2024
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Test type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Complete blood count test
• 5.3 Blood glucose test
• 5.4 Heart test
• 5.5 Infectious disease screening
• 5.6 Kidney test- renal profile
• 5.7 Cholesterol test- lipid profile test
• 5.8 Cancer test
• 5.9 Urine test
• 5.10 Antibodies test - rheumatoid factor
• 5.11 Other test types

Chapter 6 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Reagents and kits
• 6.3 Instruments
• 6.4 Software

Chapter 7 Market Estimates and Forecast, By Method, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Automated
• 7.3 Manual

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Pathology labs
• 8.4 Blood banks
• 8.5 Diagnostic centers
• 8.6 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Danaher
• 10.2 F Hoffmann-La Roche Ltd.
• 10.3 Abbott Laboratories
• 10.4 BioMerieux SA
• 10.5 Grifols
• 10.6 Becton, Dickinson and Company
• 10.7 Bio-Rad Laboratories Inc.
• 10.8 Siemens Healthineers
• 10.9 Sinocare Inc.
• 10.10 Trinity Biotech
• 10.11 Thermo Fisher Scientific Inc.
• 10.12 B. Braun Melsungen AG